Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3

Nature Communications

Volumn 7, Issue , 2016, Pages

  Tsukumo, Yoshinori ^a   Alain, Tommy ^b   Fonseca, Bruno D ^b   Nadon, Robert ^c   Sonenberg, Nahum ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; BIOLOGICAL MARKER; EIF4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TFE3; UNCLASSIFIED DRUG; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; ANTINEOPLASTIC ANTIBIOTIC; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; CARRIER PROTEIN; EIF4EBP1 PROTEIN, HUMAN; EIF4EBP2 PROTEIN, HUMAN; EIF4EBP3 PROTEIN, HUMAN; INDOLE DERIVATIVE; INITIATION FACTOR; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; PURINE DERIVATIVE; RAPAMYCIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TFE3 PROTEIN, HUMAN;

BIOMARKER; CANCER; CELLS AND CELL COMPONENTS; DRUG; GENE EXPRESSION; GENETIC ANALYSIS; INHIBITION; PROTEIN; RNA;

ARTICLE; BINDING SITE; CANCER PROGNOSIS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CRISPR CAS SYSTEM; DISEASE MARKER; DISTANT METASTASIS; ECTOPIC EXPRESSION; GENE DISRUPTION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; PROTEIN DEPLETION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; TRANSLATION REGULATION; TREATMENT RESPONSE; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; C57BL MOUSE; FEMALE; GENE EDITING; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; HELA CELL LINE; HEP-G2 CELL LINE; HUMAN; MALE; MCF-7 CELL LINE; METABOLISM; MORTALITY; MOUSE; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL PROLIFERATION; CRISPR-CAS SYSTEMS; DATABASES, GENETIC; EUKARYOTIC INITIATION FACTORS; FEMALE; GENE EDITING; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HEP G2 CELLS; HUMANS; INDOLES; MALE; MCF-7 CELLS; MICE; MICE, INBRED C57BL; PHOSPHOPROTEINS; PROTEIN BIOSYNTHESIS; PURINES; SIGNAL TRANSDUCTION; SIROLIMUS; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES;

EID: 84975497181     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11776     Document Type: Article

References (67)

1. Laplante, M., Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274-293 (2012).
2. Wullschleger, S., Loewith, R., Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471-484 (2006).
3. Zoncu, R., Efeyan, A., Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35 (2011).
4. Hara, K. et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177-189 (2002).
5. Kim, D. H. et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175 (2002).
6. Sarbassov, D. D. et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302 (2004).
7. Roux, P. P., Topisirovic, I. Regulation of mRNA translation by signaling pathways. Cold Spring Harb. Perspect. Biol. 4, 1-23 (2012).
8. Sonenberg, N., Hinnebusch, A. G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136, 731-745 (2009).
9. Gingras, A. C. et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13, 1422-1437 (1999).
10. Gingras, A. C., Raught, B., Sonenberg, N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15, 807-826 (2001).
11. Pause, A. et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature 371, 762-767 (1994).
12. Benjamin, D., Colombi, M., Moroni, C., Hall, M. N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 10, 868-880 (2011).
13. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
14. Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumours. N. Engl. J. Med. 364, 514-523 (2011).
15. Feldman, M. E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).
16. Thoreen, C. C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032 (2009).
17. Alain, T. et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res. 72, 6468-6476 (2012).
18. Dowling, R. J. et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328, 1172-1176 (2010).
19. Hsieh, A. C. et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485, 55-61 (2012).
20. Armengol, G. et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res. 67, 7551-7555 (2007).
21. Bhat, M. et al. Targeting the translation machinery in cancer. Nat. Rev. Drug Discov. 14, 261-278 (2015).
22. Graff, J. R., Konicek, B. W., Carter, J. H., Marcusson, E. G. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 68, 631-634 (2008).
23. Rojo, F. et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin. Cancer Res. 13, 81-89 (2007).
24. Poulin, F., Gingras, A. C., Olsen, H., Chevalier, S., Sonenberg, N. 4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family. J. Biol. Chem. 273, 14002-14007 (1998).
25. Tee, A. R., Proud, C. G. Caspase cleavage of initiation factor 4E-binding protein 1 yields a dominant inhibitor of cap-dependent translation and reveals a novel regulatory motif. Mol. Cell Biol. 22, 1674-1683 (2002).
26. Martina, J. A. et al. The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci. Signal. 7, ra9 (2014).
27. Roczniak-Ferguson, A. et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci. Signal. 5, ra42 (2012).
28. Settembre, C. et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 31, 1095-1108 (2012).
29. Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168 (2006).
30. Aksan, I., Goding, C. R. Targeting the microphthalmia basic helix-loop-helixleucine zipper transcription factor to a subset of E-box elements in vitro and in vivo. Mol. Cell Biol. 18, 6930-6938 (1998).
31. Hemesath, T. J. et al. microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev. 8, 2770-2780 (1994).
32. Hua, X., Liu, X., Ansari, D. O., Lodish, H. F. Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev. 12, 3084-3095 (1998).
33. Nakagawa, Y. et al. TFE3 transcriptionally activates hepatic IRS-2, participates in insulin signaling and ameliorates diabetes. Nat. Med. 12, 107-113 (2006).
34. Cunningham, J. T. et al. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450, 736-740 (2007).
35. Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380-1389 (2013).
36. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).
37. Schmidt, E. K., Clavarino, G., Ceppi, M., Pierre, P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat. Methods 6, 275-277 (2009).
38. Dowling, R. J., Zakikhani, M., Fantus, I. G., Pollak, M., Sonenberg, N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67, 10804-10812 (2007).
39. Kruger, M. et al. Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation. Mol. Cell Biol. 21, 8357-8364 (2001).
40. Fonseca, B. D. et al. The ever-evolving role of mTOR in translation. Semin. Cell Dev. Biol. 36, 102-112 (2014).
41. Thoreen, C. C. et al. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109-113 (2012).
42. Morita, M. et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 18, 698-711 (2013).
43. Thomas, H. E. et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci. Transl. Med. 4, 139ra184 (2012).
44. Poulin, F., Brueschke, A., Sonenberg, N. Gene fusion and overlapping reading frames in the mammalian genes for 4E-BP3 and MASK. J. Biol. Chem. 278, 52290-52297 (2003).
45. Chanrion, M. et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin. Cancer Res. 14, 1744-1752 (2008)
46. Wang, L., Rhodes, C. J., Lawrence, Jr J. C. Activation of mammalian target of rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1. J. Biol. Chem. 281, 24293-24303 (2006).
47. Yanagiya, A. et al. Translational homeostasis via the mRNA cap-binding protein, eIF4E. Mol. Cell 46, 847-858 (2012).
48. Hsieh, A. C. et al. Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. Sci. Signal. 8, ra116 (2015).
49. Cope, C. L. et al. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. J. Cell Sci. 127, 788-800 (2014).
50. Ilic, N., Utermark, T., Widlund, H. R., Roberts, T. M. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl Acad. Sci. USA 108, E699-E708 (2011).
51. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
52. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
53. Argani, P. et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumour entity previously included among renal cell carcinomas of children and adolescents. Am. J. Pathol. 159, 179-192 (2001).
54. Argani, P. et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am. J. Surg. Pathol. 27, 750-761 (2003).
55. Clark, J. et al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 15, 2233-2239 (1997).
56. Haq, R., Fisher, D. E. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J. Clin. Oncol. 29, 3474-3482 (2011).
57. Ladanyi, M. et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20, 48-57 (2001).
58. Tsuda, M. et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumours as candidates for therapeutic MET inhibition. Cancer Res. 67, 919-929 (2007).
59. Weterman, M. J., van Groningen, J. J., Jansen, A., van Kessel, A. G. Nuclear localization and transactivating capacities of the papillary renal cell carcinomaassociated TFE3 and PRCC (fusion) proteins. Oncogene 19, 69-74 (2000).
60. Zhang, J. H. et al. The EIF4EBP3 translational repressor is a marker of CDC73 tumour suppressor haploinsufficiency in a parathyroid cancer syndrome. Cell Death Dis. 3, 266 (2012).
61. Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumours. Science 331, 1199-1203 (2011).
62. Inaba, H. et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J. Clin. Oncol. 29, 3293-3300 (2011).
63. Tabernero, J. et al. Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumour pharmacodynamic study in patients with advanced solid tumours. J. Clin. Oncol. 26, 1603-1610 (2008).
64. Mandell, J. W. Immunohistochemical assessment of protein phosphorylation state: the dream and the reality. Histochem. Cell Biol. 130, 465-471 (2008).
65. Parekh, D. et al. Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Pancreas 9, 83-90 (1994).
66. Duluc, C. et al. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol. Med. 7, 735-753 (2015).
67. Uchida, N., Hoshino, S., Imataka, H., Sonenberg, N., Katada, T. A novel role of the mammalian GSPT/eRF3 associating with poly(A)-binding protein in Cap/Poly(A)-dependent translation. J. Biol. Chem. 277, 50286-50292 (2002).